FDA To Name First Eight EU Member State Inspection Partners Under MRA
Executive Summary
FDA is on track to name eight EU member country inspectorates as partners capable of conducting GMP surveillance inspections on behalf of the US by a Nov. 1 deadline. Another four are expected to be named by March 2018. The FDA plans to name all 28 EU member countries as partners by mid-2019.
You may also be interested in...
US Reliance On EU Drug Facility Inspections Begins In November
FDA will have completed capability assessments for eight European Union member country inspectorates by that time, with all 28 to be completed by mid-2019; EU assessment of US regulator’s inspection capabilities wraps up in July.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.